Gene Therapy and Gene Editing in 2026: An Overview

Gene therapy and gene editing are no longer science fiction: the first treatments are approved in Europe and more are close behind. This overview explains in plain language how the methods work, what is already possible, where the limits lie – and leads you to all Medizin Aktuell articles on the topic.

In short: Gene therapy replaces or adds missing or faulty genetic information. Gene editing changes the genome at a specific point, for example with the CRISPR/Cas9 “gene scissors”. So far, approved treatments are mainly for rare, serious inherited diseases. They are complex, very expensive and given only in specialised centres. Many new approaches, for example against high cholesterol, are still in clinical trials.

The methods explained

Classic gene therapy: adding a gene

A healthy copy of a gene is delivered into cells with a “gene shuttle” – usually a harmless, modified virus (for example AAV or a lentivirus). The cells can then produce the missing protein themselves. Examples approved in the EU include therapies for an inherited retinal disease, for spinal muscular atrophy in young children and for haemophilia.

CRISPR/Cas9 gene scissors: cutting precisely

The gene scissors recognise a specific site in the genome and cut there. The cell repairs the cut – in the process a gene can be switched off or changed. More about CRISPR/Cas9.

Base and prime editing: swapping letters instead of cutting

Newer tools change single “letters” of the genetic code without fully cutting the DNA double strand, which is considered more precise. Epigenetic editing only switches genes on or off without changing the sequence. Base, prime and epigenetic editing reach the clinic.

Inside or outside the body?

Ex vivo: cells (for example blood stem cells) are removed, modified in the laboratory and returned – usually after demanding chemotherapy. In vivo: the gene scissors are given as an infusion and work directly in the body, mostly in the liver. This route is simpler but newer.

What is already approved

The first approved CRISPR therapy is Casgevy for sickle cell disease and beta thalassaemia (in the EU since 2024, conditional approval). In Germany it is now given outside clinical trials.

What is being tested in trials

Our weekly magazine summarises the latest news: Future of Medicine, Episode 1 and Episode 2.

Limits, risks and open questions

  • Cost: one-off therapies often cost several million euros. How health systems will pay for them in the long run is unclear.
  • Long-term data: whether effect and safety last for decades is not yet known.
  • Side effects: unintended changes in the genome, immune reactions to the gene shuttle and, with ex vivo methods, the effects of preparatory chemotherapy.
  • Dubious offers: unapproved “anti-ageing gene therapies” are sold abroad. Why experts warn against them.

Who can receive gene therapy today?

Approved gene therapies exist only for specific diseases and are given only in specialised centres. Whether a therapy or a trial is an option is decided by the treating specialists. Ongoing trials can be found in the EU Clinical Trials register and on ClinicalTrials.gov.

Frequently asked questions

What is the difference between gene therapy and gene editing?

Classic gene therapy adds a healthy copy of a gene. Gene editing changes the existing genome at a specific point, for example with CRISPR/Cas9.

Does gene therapy change the genes of future children?

No. Approved therapies only change body cells, not egg or sperm cells. Changes to the germline are prohibited in Germany.

Is gene therapy a cure?

For some diseases, a single treatment can markedly reduce symptoms for years. How long the effect lasts is still being studied – which is why experts cautiously speak of a possible long-term effect.

German version: Gentherapie und Gen-Editing 2026: Der Überblick · See also: Longevity in 2026: what research really shows

This overview is for general information and does not replace medical advice. It is not investment advice. Last updated: November 2026; updated continuously.

Sources

  • European Medicines Agency (EMA): Casgevy – EPAR. ema.europa.eu
  • Paul-Ehrlich-Institut: Advanced therapy medicinal products (ATMP). pei.de
  • German Embryo Protection Act (ESchG), section 5. gesetze-im-internet.de
  • Individual sources on trials and approvals: see the linked articles.